Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab
January 21st 2017Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.